Rohtak News Magazine

Hemophilia Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Hemophilia Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

November 08
17:48 2022
Hemophilia Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
Hemophilia Market
DelveInsight’s “Hemophilia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Hemophilia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hemophilia, historical and forecasted epidemiology as well as the Hemophilia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Hemophilia market report provides current treatment practices, emerging drugs, the Hemophilia market share of the individual therapies, and current and forecasted Hemophilia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hemophilia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hemophilia market.

Some of the key facts of the Hemophilia Market:

  • Among the European five countries, Germany had 80,850 cases which is the highest, followed by Italy in 2021. On the other hand, Spain had the lowest number of diagnosed cases. 
  • Among the cause-specific i.e., Vehicular incidents were found to be a major cause of SCI followed by Falls. 

 

Got queries? Click here to know more about the Hemophilia Market Landscape 

Hemophilia Overview 

Hemophilia is usually an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. Blood contains many proteins called clotting factors that can help to stop bleeding.

Hemophilia is caused by a mutation or change, in one of the genes, that provides instructions for making the clotting factor proteins needed to form a blood clot. This change or mutation can prevent the clotting protein from working properly or to be missing altogether. These genes are located on the X chromosome. Males have one X and one Y chromosome (XY) and females have two X chromosomes. Males inherit the X chromosome from their mothers and the Y chromosome from their fathers. Females inherit one X chromosome from each parent.

The X chromosome contains many genes that are not present on the Y chromosome. This means that males only have one copy of most of the genes on the X chromosome, whereas females have 2 copies. Thus, males can have a disease like hemophilia if they inherit an affected X chromosome that has a mutation in either the factor VIII or factor IX gene. Females can also have hemophilia, but this is much rarer. In such cases, both X chromosomes are affected or one is affected and the other is missing or inactive. In these females, bleeding symptoms may be similar to males with hemophilia.

 

Hemophilia  Injury  Epidemiological Insight:

  • Many studies and organizations have quoted that Hemophilia A is more common than Hemophilia B, representing approximately 80–85% of the total hemophilia population.
  • Severity is the major factor of Hemophilia patients, and it can be mild, moderate, or severe depending on how much of the clotting factor is in a person’s blood.
  • In inhibitor occurrence, a clear disparity between hemophilia subtypes has been observed, with studies documenting the occurrence of 1–5% in Hemophilia B. Also, in Hemophilia B, FIX inhibitors occur almost exclusively in the extreme form, while in both severe and non-severe Hemophilia A, FVIII inhibitors occur. NORD (National Organization for Rare Disorders), 2021, estimates that less than 5% of individuals with severe hemophilia B develop “inhibitors” against factor IX replacement therapy.
  • In France, it was estimated that approximately 1,529 cases of hemophilia B had occurred in 2018. The number of cases of hemophilia B is expected to rise by 2030. According to the assessment, the prevalent cases of hemophilia B may rise to 1,675 by 2030, growing at a CAGR of 0.8%.

Hemophilia  Epidemiological Segmentation

  • Total Hemophilia prevelant cases 
  • Total Hemophilia severity specific cases 
  • Total Hemophilia with inhibitor and without inhibitor, specific cases 
  • Total Hemophilia diagnosed prevalent cases 
  • Total neurological level cases of Hemophilia  Injury

Hemophilia Market Outlook 

The Hemophilia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hemophilia market trends by analyzing the impact of current Hemophilia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Hemophilia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hemophilia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hemophilia market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Hemophilia  Market Trends

Hemophilia Key Companies 

  • Dream CIS, Inc
  • GC Biopharma Corp
  • Hoffmann – La- Roche 
  • Chugai Pharmaceuticals 
  • Bayer
  • CSL Behring 
  • And many others

Hemophilia Key Therapies

  • Emicizumab
  • Recombinant Human Coagulation 
  • Factor VIII-Fc Fusion Protein for Injection
  • Recombinant Protein-Free Factor VIII (rAHF-PFM)
  • Heparin 
  • Warfarin 

 

 

 

Table of Contents 

  • Key Insights 
  • Report Introduction 
  • Executive Summary of the Hemophilia Market 
  • Disease Background and Overview
  • Epidemiology and patient population
  • The United States 
  • EU 5
  • Hemophilia Market  Emerging Therapies
  • Hemophilia Market Outlook
  • Market Access and Reimbursement of Therapies
  • Appendix
  • Hemophilia  Market Report Methodology
  • DelveInsight Capabilities
  • Disclaimer
  • About DelveInsight

Click here to read more about Hemophilia  Market Insights 

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com

Related Articles